Press Gary Mathias 3/12/24 Gary Mathias 3/12/24 Thetis Pharmaceuticals Announces U.S. Patent for TP-317 for Treatment of Colon Cancer (3/12/2024) Read More Gary Mathias 1/16/24 Gary Mathias 1/16/24 Thetis Pharmaceuticals Progressing to Clinic with a Phase 1 Trial of TP-317 for Treatment of Mild-to-Moderate Inflammatory Bowel Disease (1/16/2024) Read More Gary Mathias 11/7/23 Gary Mathias 11/7/23 Mario Sznol, MD, Leader of the Melanoma Clinical Research Team at the Yale Cancer Center, Joins Thetis Scientific Advisory Board (11/7/2023) Read More Gary Mathias 10/12/23 Gary Mathias 10/12/23 Thetis Pharmaceuticals Announces Patent Issuance in Australia for First-in-Class RvE1 Drug (10/12/2023) Read More Gary Mathias 10/4/23 Gary Mathias 10/4/23 Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics (10/4/2023) Read More Gary Mathias 7/24/23 Gary Mathias 7/24/23 Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals (7/24/2023) Read More Gary Mathias 7/10/23 Gary Mathias 7/10/23 John Parkinson, PhD, Immunologist and Biopharma Industry Veteran, Appointed Chief Scientific Officer of Thetis Pharmaceuticals (7/10/2023) Read More Gary Mathias 6/13/23 Gary Mathias 6/13/23 Thetis Forms Australia Subsidiary to Investigate First-in-Class Oral Resolvin E1 Drug (TP-317) for Mild-to-Moderate IBD (6/13/2023) Read More Gary Mathias 6/2/23 Gary Mathias 6/2/23 Thetis Announces $2.4 Million SBIR Grant from the NIH to Develop Small Molecule Myeloid Cell Agonist to Treat Pancreatic Cancer (6/2/2023) Read More Gary Mathias 4/5/23 Gary Mathias 4/5/23 Thetis Pharmaceuticals Cancer Program to be Presented at the American Association of Cancer Research (AACR) Annual Meeting (4/5/23) Read More Gary Mathias 3/15/23 Gary Mathias 3/15/23 Thetis Announces $3 Million SBIR Grant from the NIH to Develop Oral Therapy for Mild-to-Moderate IBD (3/15/23) Read More Gary Mathias 8/24/22 Gary Mathias 8/24/22 Thetis Pharmaceuticals Announces Patent Issuance in Korea for First-in-Class Resolvin E1 Drug (8/24/2022) Read More Gary Mathias 6/15/22 Gary Mathias 6/15/22 Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug (6/15/2022) Read More Gary Mathias 4/5/22 Gary Mathias 4/5/22 Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class, Oral Resolvin E1 Therapy for Crohn’s Disease (4/5/2022) Read More answerYES Consulting 12/2/21 answerYES Consulting 12/2/21 Chris Takimoto, MD, PhD, Physician-Scientist and Oncology Drug Developer, Joins Thetis Pharmaceuticals Scientific Advisory Board (12/2/2021) Read More answerYES Consulting 10/13/21 answerYES Consulting 10/13/21 Sui Huang, MD, PhD, Pioneering Cancer Biology Researcher, Joins Thetis Pharmaceuticals Scientific Advisory Board (10/13/2021) Read More answerYES Consulting 8/23/21 answerYES Consulting 8/23/21 Thetis Pharmaceuticals Announces Patent Issuance in Japan for its Resolvin E1 candidate, TP-317, for Cancer and Autoimmune Diseases (8/23/2021) Read More answerYES Consulting 7/28/21 answerYES Consulting 7/28/21 Thetis Pharmaceuticals Receives Orphan Drug Designation from FDA for Resolvin E1 Therapy for Pancreatic Cancer (7/28/2021) Read More answerYES Consulting 7/8/21 answerYES Consulting 7/8/21 Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board (7/8/2021) Read More answerYES Consulting 1/20/21 answerYES Consulting 1/20/21 Thetis Pharmaceuticals Completes Pre-IND Meeting with FDA for its first-in-class Resolvin E1 Candidate, (1/20/2021) Read More Older Posts
Gary Mathias 3/12/24 Gary Mathias 3/12/24 Thetis Pharmaceuticals Announces U.S. Patent for TP-317 for Treatment of Colon Cancer (3/12/2024) Read More
Gary Mathias 1/16/24 Gary Mathias 1/16/24 Thetis Pharmaceuticals Progressing to Clinic with a Phase 1 Trial of TP-317 for Treatment of Mild-to-Moderate Inflammatory Bowel Disease (1/16/2024) Read More
Gary Mathias 11/7/23 Gary Mathias 11/7/23 Mario Sznol, MD, Leader of the Melanoma Clinical Research Team at the Yale Cancer Center, Joins Thetis Scientific Advisory Board (11/7/2023) Read More
Gary Mathias 10/12/23 Gary Mathias 10/12/23 Thetis Pharmaceuticals Announces Patent Issuance in Australia for First-in-Class RvE1 Drug (10/12/2023) Read More
Gary Mathias 10/4/23 Gary Mathias 10/4/23 Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics (10/4/2023) Read More
Gary Mathias 7/24/23 Gary Mathias 7/24/23 Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals (7/24/2023) Read More
Gary Mathias 7/10/23 Gary Mathias 7/10/23 John Parkinson, PhD, Immunologist and Biopharma Industry Veteran, Appointed Chief Scientific Officer of Thetis Pharmaceuticals (7/10/2023) Read More
Gary Mathias 6/13/23 Gary Mathias 6/13/23 Thetis Forms Australia Subsidiary to Investigate First-in-Class Oral Resolvin E1 Drug (TP-317) for Mild-to-Moderate IBD (6/13/2023) Read More
Gary Mathias 6/2/23 Gary Mathias 6/2/23 Thetis Announces $2.4 Million SBIR Grant from the NIH to Develop Small Molecule Myeloid Cell Agonist to Treat Pancreatic Cancer (6/2/2023) Read More
Gary Mathias 4/5/23 Gary Mathias 4/5/23 Thetis Pharmaceuticals Cancer Program to be Presented at the American Association of Cancer Research (AACR) Annual Meeting (4/5/23) Read More
Gary Mathias 3/15/23 Gary Mathias 3/15/23 Thetis Announces $3 Million SBIR Grant from the NIH to Develop Oral Therapy for Mild-to-Moderate IBD (3/15/23) Read More
Gary Mathias 8/24/22 Gary Mathias 8/24/22 Thetis Pharmaceuticals Announces Patent Issuance in Korea for First-in-Class Resolvin E1 Drug (8/24/2022) Read More
Gary Mathias 6/15/22 Gary Mathias 6/15/22 Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug (6/15/2022) Read More
Gary Mathias 4/5/22 Gary Mathias 4/5/22 Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class, Oral Resolvin E1 Therapy for Crohn’s Disease (4/5/2022) Read More
answerYES Consulting 12/2/21 answerYES Consulting 12/2/21 Chris Takimoto, MD, PhD, Physician-Scientist and Oncology Drug Developer, Joins Thetis Pharmaceuticals Scientific Advisory Board (12/2/2021) Read More
answerYES Consulting 10/13/21 answerYES Consulting 10/13/21 Sui Huang, MD, PhD, Pioneering Cancer Biology Researcher, Joins Thetis Pharmaceuticals Scientific Advisory Board (10/13/2021) Read More
answerYES Consulting 8/23/21 answerYES Consulting 8/23/21 Thetis Pharmaceuticals Announces Patent Issuance in Japan for its Resolvin E1 candidate, TP-317, for Cancer and Autoimmune Diseases (8/23/2021) Read More
answerYES Consulting 7/28/21 answerYES Consulting 7/28/21 Thetis Pharmaceuticals Receives Orphan Drug Designation from FDA for Resolvin E1 Therapy for Pancreatic Cancer (7/28/2021) Read More
answerYES Consulting 7/8/21 answerYES Consulting 7/8/21 Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board (7/8/2021) Read More
answerYES Consulting 1/20/21 answerYES Consulting 1/20/21 Thetis Pharmaceuticals Completes Pre-IND Meeting with FDA for its first-in-class Resolvin E1 Candidate, (1/20/2021) Read More